Leveraging Real World Evidence to Support Oncology Targeted Therapies

Access the White Paper: Leveraging Real World Evidence to Support Oncology Targeted Therapies

As precision oncology evolves, generating RWE is becoming more important than ever, particularly for novel or under-tested biomarkers.

With IQVIA’s Oncology Evidence Network (OEN), pharma companies can accelerate clinical development, improve market access, and increase adoption of targeted therapies.

Access it now to learn more about:

Why RWE is essential for targeted therapies - and the unique challenges it presents
Key hurdles of novel biomarkers, from low prevalence to testing variability
How IQVIA’s OEN enables advantages in linked biomarker and clinical data, retrospective testing and AI-powered analysis
Proven strategies to accelerate timelines and drive adoption of therapies
The role of cross-functional collaboration in shaping the future of precision oncology

Simply complete the form to download your free White Paper.

Work Email Address*

Role

Country*

Yes, I would like to be contacted by an IQVIA expert

I have read and agree to the below privacy policies

By ticking this box, you agree to receive emails from Citeline, and carefully selected partners

Lead Source - PI Partner

Primary Product Interest*

You agree Citeline and IQVIA may contact you directly about industry news, products, services and events that may be of interest to you subject to the privacy policies of Citeline and IQVIA.

Accelerate clinical development in oncology with IQVIA’s RWE solutions

Access the White Paper: Leveraging Real World Evidence to Support Oncology Targeted Therapies

Simply complete the form to download your free White Paper.